2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

4:30PM-6:00PM: Abstract Number: 3156

IL17 Promotes Development of Autoreactive Early Stage B Cells in Distinct Regions of the Spleen Follicle

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

4:30PM-6:00PM: Abstract Number: 3193

Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis

Rheumatoid Arthritis Animal Models II

4:30PM-6:00PM: Abstract Number: 3158

Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 3214

Impaired Phagocytosis of Apoptotic Cells in Pristane-Induced Lupus Simulates the Clearance Defect in Human SLE

Systemic Lupus Erythematosus - Animal Models

4:30PM-6:00PM: Abstract Number: 3199

In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3226

Increased Serum Levels of IgG Antibodies Against to Alpha-Enolase Are Associated with Severity of Oral Ulcers in Patients with Behcet’s Disease

Vasculitis IV

4:30PM-6:00PM: Abstract Number: 3206

Inflammation on MRI in Sacroiliac-Joints and Spine Is Longitudinally Related to Disease Activity in Male but Not in Female Patients with Axial Spondyloarthritis: 2-Year Data from the DESIR Cohort

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects, Imaging and Biomarkers

4:30PM-6:00PM: Abstract Number: 3188

Inhibition of Lymphatic Muscle Contraction By Lymphatic Endothelial iNOS Impairs Lymph Drainage from Arthritic Joints in TNF-Tg Mice and Is Prevented By Herbal Drugs

Rheumatoid Arthritis Animal Models II

4:30PM-6:00PM: Abstract Number: 3184

Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam

Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission

4:30PM-6:00PM: Abstract Number: 3192

KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA

Rheumatoid Arthritis Animal Models II

4:30PM-6:00PM: Abstract Number: 3217

Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Animal Models

4:30PM-6:00PM: Abstract Number: 3180

Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions

4:30PM-6:00PM: Abstract Number: 3153

Microrna-155/PU.1 Axis As an Epigenetic Regulator of B-Cells in Rheumatoid Arthritis

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

4:30PM-6:00PM: Abstract Number: 3190

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

Rheumatoid Arthritis Animal Models II

4:30PM-6:00PM: Abstract Number: 3176

New Prospects for Interpreting Bony Depressions in Juvenile Idiopathic Arthritis: A Novel MRI Computer-Assisted Technique for Detection of Erosive Progression

Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].